During this presentation we welcome, PolyPid. PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections.

This Company Webcast was recorded during the Lytham Partners Fall 2024 Investor Conference.